Y. Mostovoy, L. Rasputina, D. Didenko, V. Rasputin, I. Mezhiievska, A. Broniuk
{"title":"糖尿病患者急性心肌梗死:心脏保护的可能性和便利性","authors":"Y. Mostovoy, L. Rasputina, D. Didenko, V. Rasputin, I. Mezhiievska, A. Broniuk","doi":"10.30978/HV2018-4-34","DOIUrl":null,"url":null,"abstract":"The aim — to evaluate the efficacy and safety of addition of a solution containing 4.2 g of arginine hydrochloride and 2.0 g L‑carnitine to standard therapy of patients with acute coronary syndrome (ACS) with ST segment elevation and concomitant type 2 diabetes mellitus (DM) after revascularization through primary coronary intervention (PCI). Materials and methods. The study involved 60 patients (mean age 64.3 ± 1.6 years) with ACS with ST segment elevation of up to 6 hours’ duration and concomitant type 2 DM, who had had urgent coronary angiography and stenting of the infarction‑dependent artery. The patients were divided into two groups: group І — 30 persons to whom standard intravenous infusion was given of a preparation containing 4.2 g of arginine hydrochloride and 2.0 g of L‑carnitine, 100 ml a day for 7 days, and group ІІ — 30 individuals who did not receive additional therapy. A general clinical examination was conducted with an assessment of complaints and anamnesis, objective physical examination data and the results of additional diagnostic methods. The level of troponin I and resolution of ST segment were determined on the 1st, 3rd and 7th days. Results and discussion. Patients in both groups were compared according to the main clinical and anthropometric indices, prescribed drug therapy, features of atherosclerotic damage of coronary artery, duration of ischemic period, troponin I level on the 1st, 3rd and 7th days (all p > 0.05). The value of ST segment elevation at the time of hospitalization in the patients of both groups did not differ significantly: 4.8 ± 0.17 and 4.5 ± 0.15 mm respectively, but on day 3 it was lower in group І (2.37 ± 0.14 mm) compared with group II 3.2 ± 0.17 mm, p = 0.05). In patients of group I, unlike such of group II, there was a significant decrease in the level of aspartate aminotransferase and alanine aminotransferase on day 7. The decrease in group I was more pronounced than in group II (p = 0.048 and p = 0.032, respectively). Conclusions. The addition of amino acids complexes (4.2g of arginine hydrochloride and 2.0 g of L‑carnitine) to drug therapy of patients with ACS with ST segment elevation and concomitant DM type 2 after myocardial revascularization, contributes to a rapid decrease in the level of troponin I and reduction in ST segment elevation and is not accompanied by side effects.","PeriodicalId":23425,"journal":{"name":"UMJ Heart & Vessels","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Acute myocardial infarction in patients with diabetes mellitus: possibility and expediency of cardioprotection\",\"authors\":\"Y. Mostovoy, L. Rasputina, D. Didenko, V. Rasputin, I. Mezhiievska, A. Broniuk\",\"doi\":\"10.30978/HV2018-4-34\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The aim — to evaluate the efficacy and safety of addition of a solution containing 4.2 g of arginine hydrochloride and 2.0 g L‑carnitine to standard therapy of patients with acute coronary syndrome (ACS) with ST segment elevation and concomitant type 2 diabetes mellitus (DM) after revascularization through primary coronary intervention (PCI). Materials and methods. The study involved 60 patients (mean age 64.3 ± 1.6 years) with ACS with ST segment elevation of up to 6 hours’ duration and concomitant type 2 DM, who had had urgent coronary angiography and stenting of the infarction‑dependent artery. The patients were divided into two groups: group І — 30 persons to whom standard intravenous infusion was given of a preparation containing 4.2 g of arginine hydrochloride and 2.0 g of L‑carnitine, 100 ml a day for 7 days, and group ІІ — 30 individuals who did not receive additional therapy. A general clinical examination was conducted with an assessment of complaints and anamnesis, objective physical examination data and the results of additional diagnostic methods. The level of troponin I and resolution of ST segment were determined on the 1st, 3rd and 7th days. Results and discussion. Patients in both groups were compared according to the main clinical and anthropometric indices, prescribed drug therapy, features of atherosclerotic damage of coronary artery, duration of ischemic period, troponin I level on the 1st, 3rd and 7th days (all p > 0.05). The value of ST segment elevation at the time of hospitalization in the patients of both groups did not differ significantly: 4.8 ± 0.17 and 4.5 ± 0.15 mm respectively, but on day 3 it was lower in group І (2.37 ± 0.14 mm) compared with group II 3.2 ± 0.17 mm, p = 0.05). In patients of group I, unlike such of group II, there was a significant decrease in the level of aspartate aminotransferase and alanine aminotransferase on day 7. The decrease in group I was more pronounced than in group II (p = 0.048 and p = 0.032, respectively). Conclusions. The addition of amino acids complexes (4.2g of arginine hydrochloride and 2.0 g of L‑carnitine) to drug therapy of patients with ACS with ST segment elevation and concomitant DM type 2 after myocardial revascularization, contributes to a rapid decrease in the level of troponin I and reduction in ST segment elevation and is not accompanied by side effects.\",\"PeriodicalId\":23425,\"journal\":{\"name\":\"UMJ Heart & Vessels\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"UMJ Heart & Vessels\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30978/HV2018-4-34\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"UMJ Heart & Vessels","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30978/HV2018-4-34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
目的:评价急性冠脉综合征(ACS) ST段抬高合并2型糖尿病(DM)患者经初级冠状动脉介入治疗(PCI)血运重建术后,加入含有4.2 g盐酸精氨酸和2.0 g左旋肉碱的溶液进行标准治疗的疗效和安全性。材料和方法。该研究涉及60例ACS患者(平均年龄64.3±1.6岁),ST段抬高持续时间长达6小时,并伴有2型糖尿病,这些患者曾接受紧急冠状动脉造影和梗死依赖动脉支架置入术。患者被分为两组:І组- 30人给予标准静脉输注含有4.2 g盐酸精氨酸和2.0 g左旋肉碱的制剂,每天100毫升,持续7天;ІІ组- 30人不接受额外治疗。进行一般临床检查,评估主诉和记忆,客观体格检查资料和其他诊断方法的结果。分别于第1、3、7天测定肌钙蛋白I水平和ST段分辨率。结果和讨论。比较两组患者的主要临床及人体测量指标、处方药物治疗、冠状动脉粥样硬化损伤特征、缺血时间、第1、3、7天肌钙蛋白I水平(均p > 0.05)。两组患者入院时ST段抬高值无显著差异,分别为4.8±0.17 mm和4.5±0.15 mm,但第3天І组ST段抬高值(2.37±0.14 mm)低于ⅱ组(3.2±0.17 mm, p = 0.05)。I组患者与II组患者不同,第7天天冬氨酸转氨酶和丙氨酸转氨酶水平明显下降。I组较II组下降更明显(p = 0.048, p = 0.032)。结论。在心肌血运重建术后伴有ST段抬高的ACS患者药物治疗中加入氨基酸复合物(4.2g盐酸精氨酸和2.0 g左旋肉碱),可使肌钙蛋白I水平迅速降低,ST段抬高降低,且无副作用。
Acute myocardial infarction in patients with diabetes mellitus: possibility and expediency of cardioprotection
The aim — to evaluate the efficacy and safety of addition of a solution containing 4.2 g of arginine hydrochloride and 2.0 g L‑carnitine to standard therapy of patients with acute coronary syndrome (ACS) with ST segment elevation and concomitant type 2 diabetes mellitus (DM) after revascularization through primary coronary intervention (PCI). Materials and methods. The study involved 60 patients (mean age 64.3 ± 1.6 years) with ACS with ST segment elevation of up to 6 hours’ duration and concomitant type 2 DM, who had had urgent coronary angiography and stenting of the infarction‑dependent artery. The patients were divided into two groups: group І — 30 persons to whom standard intravenous infusion was given of a preparation containing 4.2 g of arginine hydrochloride and 2.0 g of L‑carnitine, 100 ml a day for 7 days, and group ІІ — 30 individuals who did not receive additional therapy. A general clinical examination was conducted with an assessment of complaints and anamnesis, objective physical examination data and the results of additional diagnostic methods. The level of troponin I and resolution of ST segment were determined on the 1st, 3rd and 7th days. Results and discussion. Patients in both groups were compared according to the main clinical and anthropometric indices, prescribed drug therapy, features of atherosclerotic damage of coronary artery, duration of ischemic period, troponin I level on the 1st, 3rd and 7th days (all p > 0.05). The value of ST segment elevation at the time of hospitalization in the patients of both groups did not differ significantly: 4.8 ± 0.17 and 4.5 ± 0.15 mm respectively, but on day 3 it was lower in group І (2.37 ± 0.14 mm) compared with group II 3.2 ± 0.17 mm, p = 0.05). In patients of group I, unlike such of group II, there was a significant decrease in the level of aspartate aminotransferase and alanine aminotransferase on day 7. The decrease in group I was more pronounced than in group II (p = 0.048 and p = 0.032, respectively). Conclusions. The addition of amino acids complexes (4.2g of arginine hydrochloride and 2.0 g of L‑carnitine) to drug therapy of patients with ACS with ST segment elevation and concomitant DM type 2 after myocardial revascularization, contributes to a rapid decrease in the level of troponin I and reduction in ST segment elevation and is not accompanied by side effects.